|
🐢
|
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
12 auth.
D. Baeten,
J. Sieper,
J. Braun,
X. Baraliakos,
M. Dougados,
P. Emery,
...
A. Deodhar,
B. Porter,
R. Martin,
M. Andersson,
S. Mpofu,
H. Richards
|
9 |
2015 |
9
🐢
|
|
🐜
|
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
15 auth.
I. McInnes,
P. Mease,
B. Kirkham,
A. Kavanaugh,
C. Ritchlin,
P. Rahman,
D. Heijde,
R. Landewé,
P. Conaghan,
A. Gottlieb,
...
H. Richards,
L. Pricop,
G. Ligozio,
M. Patekar,
S. Mpofu
|
9 |
2015 |
9
🐜
|
|
🐜
|
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
12 auth.
P. Mease,
I. McInnes,
B. Kirkham,
A. Kavanaugh,
P. Rahman,
D. M. van der Heijde,
...
R. Landewé,
P. Nash,
L. Pricop,
Jiacheng Yuan,
H. Richards,
S. Mpofu
|
9 |
2015 |
9
🐜
|
|
🐢
|
Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study
10 auth.
K. Papp,
R. Langley,
B. Sigurgeirsson,
M. Abe,
Diane Baker,
P. Konno,
...
S. Haemmerle,
H. Thurston,
C. Papavassilis,
H. Richards
|
8 |
2013 |
8
🐢
|
|
🐜
|
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
13 auth.
M. Genovese,
P. Durez,
H. Richards,
J. Supronik,
E. Dokoupilova,
V. Mazurov,
J. Aelion,
Sang-Heon Lee,
C. Codding,
H. Kellner,
...
T. Ikawa,
S. Hugot,
S. Mpofu
|
8 |
2012 |
8
🐜
|
|
🐢
|
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
10 auth.
J. Braun,
X. Baraliakos,
A. Deodhar,
D. Baeten,
J. Sieper,
P. Emery,
...
A. Readie,
R. Martin,
S. Mpofu,
H. Richards
|
7 |
2016 |
7
🐢
|
|
🐜
|
Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus.
10 auth.
P. Lee,
Yi Li,
H. Richards,
Fay Chan,
Haoyang Zhuang,
S. Narain,
...
E. Butfiloski,
E. Sobel,
W. Reeves,
M. Segal
|
7 |
2007 |
7
🐜
|
|
🦁
|
Interleukin 6 Dependence of Anti-DNA Antibody Production: Evidence for Two Pathways of Autoantibody Formation in Pristane-induced Lupus
H. Richards,
M. Satoh,
M. Shaw,
C. Libert,
V. Poli,
W. Reeves
|
7 |
1998 |
7
🦁
|
|
🐢
|
Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support.
R. Jump,
M. Robinson,
A. Armstrong,
Elena V. Barnes,
K. Kilbourn,
H. Richards
|
7 |
2005 |
7
🐢
|
|
🐢
|
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
9 auth.
J. Sieper,
A. Deodhar,
H. Marzo-Ortega,
J. Aelion,
R. Blanco,
Tseng Jui-Cheng,
...
M. Andersson,
B. Porter,
H. Richards
|
7 |
2016 |
7
🐢
|
|
🐢
|
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study
8 auth.
F. Blanco,
R. Möricke,
E. Dokoupilova,
C. Codding,
J. Neal,
M. Andersson,
...
Susanne Rohrer,
H. Richards
|
7 |
2017 |
7
🐢
|
|
🐢
|
Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis.
7 auth.
M. Tucci,
Elena V. Barnes,
E. Sobel,
B. Croker,
M. Segal,
W. Reeves,
...
H. Richards
|
7 |
2004 |
7
🐢
|
